Covid-19 Vaccine from Beijing Appears Safe, Initial Shows Good Response

NHS 'to start COVID vaccination of all adults by end of January'

NHS 'to start COVID vaccination of all adults by end of January'

Almost a million people in China have taken an experimental coronavirus vaccine through the country's emergency use program as of Wednesday, according to vaccine developer China National Pharmaceutical Group (Sinopharm).

"In emergency use, we now have used it on almost a million people".

Essential workers and other groups vulnerable to the virus have been included in the program, which was launched in July, with three COVID-19 vaccine candidates.

A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing, capital of China, March 16, 2020.

Although the final phase of testing of this vaccine developed by the Chinese company Sinopharm has not yet been completed, the Chinese government has given permission to apply this experimental vaccine to patients in an emergency.

Celtics to sign Tristan Thompson to reported 2-year, $19M deal
The views on this page do not necessarily represent the views of the National Basketball Association or its clubs. Chris Haynes of Yahoo Sports broke the news, while Joe Vardon of The Athletic provided the contract details.

No serious adverse reaction has been reported from those who received the vaccine in emergency use, Sinopharm said in an article on social media WeChat, citing Chairman Liu Jingzhen from a recent media interview. It uses a modified cold virus called adenovirus, and it carries a little piece of the coronavirus into the body to train the immune system to recognize and attack it.

The most common symptom was injection-site pain, which is in accordance with previous findings for another Covid-19 vaccine from Sinopharm, Beijing.

Phase II vaccine trials provide important preliminary data but don't prove whether they ultimately prevent people from getting sick.

"Our progress so far, from research and development to clinical trials and production and emergency use, is leading the world in all aspects", he said without offering evidence. Drugmaker AstraZeneca is working with the university on the vaccine.

Since the announcement by the American company Pfizer to make 95 percent effective corona vaccine, many countries have claimed to make effective vaccine. The researchers also stress that 240 participants were over the age of 70 and their immune responses were similar to younger people in this clinical trial as well as the results from the younger cohort from Phase I. This is a very important result given how older adults are one of the most-at-risk groups. Demand is clearly high, and several wealthy nations already have their pre-orders in place.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.